Michael Schirmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2016400/publications.pdf

Version: 2024-02-01

362 papers 18,568 citations

69 h-index 121 g-index

399 all docs 399 docs citations

times ranked

399

17001 citing authors

#	Article	IF	CITATIONS
1	Development of an environmental contextual factor item set relevant to global functioning and health in patients with axial spondyloarthritis. Rheumatology, 2022, 61, 2054-2062.	1.9	4
2	Dr. Berti et al reply. Journal of Rheumatology, 2022, 49, 234.2-234.	2.0	О
3	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. Journal of Scleroderma and Related Disorders, 2022, 7, 168-178.	1.7	9
4	Low Bone Mineral Density in Hemophiliacs. Frontiers in Medicine, 2022, 9, 794456.	2.6	15
5	Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology. Mayo Clinic Proceedings, 2022, 97, 250-260.	3.0	10
6	Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides—Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort. Cells, 2022, 11, 536.	4.1	4
7	The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210744.	2.7	7
8	Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the <scp>INBUILD</scp> Trial. Arthritis and Rheumatology, 2022, 74, 1039-1047.	5.6	44
9	Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Annals of the Rheumatic Diseases, 2022, 81, 861-867.	0.9	35
10	Cardiovascular Risks and Risk Stratification in Inflammatory Joint Diseases: A Cross-Sectional Study. Frontiers in Medicine, 2022, 9, 786776.	2.6	6
11	Placebo-Related Adverse Events in Rheumatoid Arthritis. Biomolecules, 2022, 12, 303.	4.0	O
12	Immunological Memory and Affinity Maturation After Vaccination in Patients With Propionic Acidemia. Frontiers in Immunology, 2022, 13, 774503.	4.8	2
13	Rheumatoid interstitial lung disease in Canterbury New Zealand: prevalence, risk factors and long-term outcomesâ€"protocol for a population-based retrospective study. BMJ Open, 2022, 12, e050934.	1.9	2
14	Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A <scp>Pharmacogenomicsâ€Driven</scp> Machine Learning Approach. Arthritis Care and Research, 2022, 74, 879-888.	3.4	15
15	Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritisâ€associated interstitial lung disease and idiopathic pulmonary fibrosis. FASEB Journal, 2022, 36, e22336.	0.5	27
16	Looking ahead: giant-cell arteritis in 10 years time. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210963.	2.7	10
17	Post-Mortem Interval of Human Skeletal Remains Estimated with Handheld NIR Spectrometry. Biology, 2022, 11, 1020.	2.8	7
18	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.9	120

#	Article	IF	CITATIONS
19	Erectile Dysfunction in Men With Psoriatic Arthritis: A Population-based Cohort Study. Journal of Rheumatology, 2021, 48, 527-532.	2.0	O
20	Reply to: What could a new disease activity score for polymyalgia rheumatica do better?. Nature Reviews Rheumatology, 2021, 17, 185-186.	8.0	2
21	Hyperspectral imaging as a diagnostic tool to differentiate between amalgam tattoos and other dark pigmented intraoral lesions. Journal of Biophotonics, 2021, 14, e202000424.	2.3	4
22	Hospitalization Rates Are Highest in the First 5 Years of Systemic Sclerosis: Results From a Population-based Cohort (1980–2016). Journal of Rheumatology, 2021, 48, 877-882.	2.0	6
23	Dr. Elfishawi, et al reply. Journal of Rheumatology, 2021, 48, 468.2-468.	2.0	0
24	Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110375.	2.7	19
25	Editorial. Journal of Clinical Rheumatology, 2021, 27, 173-174.	0.9	1
26	Prognosis and Disease Activity. Rare Diseases of the Immune System, 2021, , 57-64.	0.1	0
27	Erectile Dysfunction and Cardiovascular Risk in Men With Rheumatoid Arthritis: A Population-based Cohort Study. Journal of Rheumatology, 2021, 48, 1641-1647.	2.0	7
28	Increased Risk of Valvular Heart Disease in Systemic Sclerosis: An Underrecognized Cardiac Complication. Journal of Rheumatology, 2021, 48, 1047-1052.	2.0	9
29	Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply. Rheumatology, 2021, 60, e262-e263.	1.9	0
30	Adamantiadesâ€Behçet's disease (Behçet's disease) and COVIDâ€19. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e541-e543.	2.4	12
31	New perspectives of hyperspectral imaging for clinical research. NIR News, 2021, 32, 5-13.	0.3	13
32	Systemic sclerosis portends increased risk of conduction and rhythm abnormalities at diagnosis and during disease course: A US population-based cohort. Journal of Scleroderma and Related Disorders, 2021, 6, 277-285.	1.7	2
33	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. Seminars in Arthritis and Rheumatism, 2021, , .	3.4	3
34	IL-23 amplifies the epithelial-mesenchymal transition of mechanically conditioned alveolar epithelial cells in rheumatoid arthritis-associated interstitial lung disease through mTOR/S6 signaling. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L1006-L1022.	2.9	8
35	Rasch Model of the COVID-19 Symptom Checklistâ€"A Psychometric Validation Study. Viruses, 2021, 13, 1762.	3.3	2
36	A novel humanized model of rheumatoid arthritis associated lung disease. Clinical Immunology, 2021, 230, 108813.	3.2	2

#	Article	IF	CITATIONS
37	Identification of Five Quality Needs for Rheumatology (Text Analysis and Literature Review). Frontiers in Medicine, 2021, 8, 757102.	2.6	3
38	Changes in the Presentation of Incident Gout and the Risk of Subsequent Flares: A Population-based Study over 20 Years. Journal of Rheumatology, 2020, 47, 613-618.	2.0	9
39	Increased hospitalization rates following heart failure diagnosis in rheumatoid arthritis as compared to the general population. Seminars in Arthritis and Rheumatism, 2020, 50, 25-29.	3.4	2
40	2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Annals of the Rheumatic Diseases, 2020, 79, 61-68.	0.9	84
41	Definition and construct validation of clinically relevant cutoffs on the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire. Seminars in Arthritis and Rheumatism, 2020, 50, 261-265.	3.4	7
42	Longitudinal relationships between rheumatoid factor and cytokine expression by immunostimulated peripheral blood lymphocytes from patients with rheumatoid arthritis: New insights into B-cell activation. Clinical Immunology, 2020, 211, 108342.	3.2	6
43	CD28 and CD57 define four populations with distinct phenotypic properties within human CD8 ⁺ TÂcells. European Journal of Immunology, 2020, 50, 363-379.	2.9	34
44	Morbidity and Mortality of Large-Vessel Vasculitides. Current Rheumatology Reports, 2020, 22, 86.	4.7	9
45	Personalized medicine in Austria: expectations and limitations. Personalized Medicine, 2020, 17, 423-428.	1.5	3
46	Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nature Reviews Rheumatology, 2020, 16, 481-495.	8.0	54
47	Polymyalgia Rheumatica and Giant Cell Arteritis. JAMA - Journal of the American Medical Association, 2020, 324, 993.	7.4	34
48	Observation of a 27 Days Periodicity in Melanoma Diagnosis. Biophysical Reviews and Letters, 2020, 15, 275-291.	0.8	2
49	Polypharmacy in Middle-European Rheumatoid Arthritis-Patients: A Retrospective Longitudinal Cohort Analysis With Systematic Literature Review. Frontiers in Medicine, 2020, 7, 573542.	2.6	10
50	Reply. Arthritis and Rheumatology, 2020, 72, 1776-1776.	5.6	0
51	Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Mayo Clinic Proceedings, 2020, 95, 1404-1419.	3.0	71
52	Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985–2014. Annals of the Rheumatic Diseases, 2020, 79, 440-444.	0.9	131
53	The future of pathology is digital. Pathology Research and Practice, 2020, 216, 153040.	2.3	65
54	Cardiovascular Risk Factors and Atherosclerotic Cardiovascular Events Among Incident Cases of Systemic Sclerosis: Results From a Population-Based Cohort (1980-2016). Mayo Clinic Proceedings, 2020, 95, 1369-1378.	3.0	16

#	Article	IF	Citations
55	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	1.9	56
56	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	1.9	128
57	Comparison of structure and composition of a fossil Champsosaurus vertebra with modern Crocodylidae vertebrae: A multi-instrumental approach. Journal of the Mechanical Behavior of Biomedical Materials, 2020, 104, 103668.	3.1	0
58	Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis. Rheumatology, 2020, 59, 3229-3236.	1.9	30
59	Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 79-83.	0.8	1
60	Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort. Nephrology Dialysis Transplantation, 2019, 34, 1508-1517.	0.7	46
61	Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 358-375.	2.4	160
62	Optimization of flare management in patients with rheumatoid arthritis: results of a randomized controlled trial. Clinical Rheumatology, 2019, 38, 3025-3032.	2.2	7
63	The Incidence of Arterial and Venous Thrombosis in Antineutrophil Cytoplasmic Antibody–associated Vasculitis. Journal of Rheumatology, 2019, 46, 1243-1243.	2.0	3
64	Treat to Target. Rheumatic Disease Clinics of North America, 2019, 45, 549-567.	1.9	9
65	Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity. Mayo Clinic Proceedings, 2019, 94, 2241-2248.	3.0	30
66	Mechanisms of lung disease development in rheumatoid arthritis. Nature Reviews Rheumatology, 2019, 15, 581-596.	8.0	78
67	Reply. Arthritis and Rheumatology, 2019, 71, 1769-1770.	5 . 6	0
68	Pulmonary Complications of Rheumatoid Arthritis. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 194-207.	2.1	29
69	Depletion of activated macrophages with a folate receptor-beta-specific antibody improves symptoms in mouse models of rheumatoid arthritis. Arthritis Research and Therapy, 2019, 21, 143.	3 . 5	29
70	Trends in Prevalence of Functional Disability in Rheumatoid Arthritis Compared With the General Population. Mayo Clinic Proceedings, 2019, 94, 1035-1039.	3.0	24
71	Spontaneous Pneumomediastinum in Connective Tissue Diseases. Journal of Clinical Rheumatology, 2019, 25, 239-245.	0.9	9
72	Older Drugs With Limited Trial Evidence: Are They Worth the Expense?. Annals of Internal Medicine, 2019, 171, 602.	3.9	3

#	Article	IF	CITATIONS
73	Comparison of Biologic Discontinuation in Patients With Elderlyâ€Onset Versus Youngerâ€Onset Rheumatoid Arthritis. ACR Open Rheumatology, 2019, 1, 627-631.	2.1	5
74	Profibrotic effect of IL-17A and elevated IL-17RA in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated lung disease support a direct role for IL-17A/IL-17RA in human fibrotic interstitial lung disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L487-L497.	2.9	115
75	Association of Smoking and Obesity on the Risk of Developing Primary Sj \tilde{A} ¶gren Syndrome: A Population-based Cohort Study. Journal of Rheumatology, 2019, 46, 727-730.	2.0	13
76	Clinical Characteristics of Ocular Sarcoidosis: A Population-Based Study 1976–2013. Ocular Immunology and Inflammation, 2019, 27, 389-395.	1.8	39
77	Management and Comorbidities in Middle-European Patients with Rheumatoid Arthritis: A Retrospective, Cross-sectional Comparison with COMORA Data. Open Rheumatology Journal, 2019, 13, 94-97.	0.2	1
78	Older Drugs With Limited Trial Evidence: Are They Worth the Expense? The Case of Repository Corticotropin Marketed as H.P. Acthar Gel. Annals of Internal Medicine, 2019, 170, 791.	3.9	9
79	Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR). Annals of the Rheumatic Diseases. 2018. 77. annrheumdis-2017-212565.	0.9	29
80	Differential clinical presentation of Adamantiades–Behçet's disease in nonâ€endemic and endemic areas: retrospective data from a Middleâ€European cohort study. International Journal of Rheumatic Diseases, 2018, 21, 2151-2157.	1.9	4
81	Tocilizumab for the treatment of giant cell arteritis. Expert Review of Clinical Immunology, 2018, 14, 339-349.	3.0	23
82	Common Language Description of the Term Rheumatic and Musculoskeletal Diseases (<scp>RMD</scp> s) for Use in Communication With the Lay Public, Healthcare Providers, and Other Stakeholders Endorsed by the European League Against Rheumatism (<scp>EULAR</scp>) and the American College of Rheumatology (<scp>ACR</scp>). Arthritis and Rheumatology, 2018, 70, 826-831.	5.6	21
83	FDG-PET/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1250-1269.	6.4	332
84	Clinical Correlates, Outcomes, and Predictors of Inflammatory Ocular Disease Associated with Rheumatoid Arthritis in the Biologic Era. Journal of Rheumatology, 2018, 45, 595-603.	2.0	25
85	Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasoundâ€Guided Synovial Biopsies in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 841-854.	5.6	44
86	Orthopedic Surgery Among Patients With Rheumatoid Arthritis: A Populationâ€Based Study to Identify Risk Factors, Sex Differences, and Time Trends. Arthritis Care and Research, 2018, 70, 1546-1550.	3 . 4	16
87	The Rising Incidence of Gout and the Increasing Burden of Comorbidities: A Population-based Study over 20 Years. Journal of Rheumatology, 2018, 45, 574-579.	2.0	111
88	Treatments for giant cell arteritis: Meta-analysis and assessment of estimates reliability using the fragility index. Seminars in Arthritis and Rheumatism, 2018, 48, 77-82.	3.4	21
89	Hospitalisation rates among patients with primary Sjögren's syndrome: a population-based study, 1995–2016. RMD Open, 2018, 4, e000575.	3.8	7
90	Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology, 2018, 57, ii32-ii42.	1.9	136

#	Article	IF	CITATIONS
91	Reply. Arthritis Care and Research, 2018, 70, 953-954.	3.4	O
92	Comparable Rates of Glucocorticoidâ€Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population. Arthritis Care and Research, 2018, 70, 643-647.	3.4	37
93	Subgrouping fibromyalgia according to prevalence data may lead to a new therapeutic concept. Rheumatology International, 2018, 38, 535-536.	3.0	1
94	Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 48-54.	0.9	194
95	Risk of Obstructive Sleep Apnea and Its Association with Cardiovascular and Noncardiac Vascular Risk in Patients with Rheumatoid Arthritis: A Population-based Study. Journal of Rheumatology, 2018, 45, 45-52.	2.0	10
96	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. RMD Open, 2018, 4, e000756.	3.8	17
97	EULAR â€~points to consider' for the conduction of workforce requirement studies in rheumatology. RMD Open, 2018, 4, e000780.	3.8	16
98	Clinical infrared microscopic imaging: An overview. Pathology Research and Practice, 2018, 214, 1532-1538.	2.3	11
99	Assessing Mortality Models in Systemic Sclerosis-Related Interstitial Lung Disease. Lung, 2018, 196, 409-416.	3.3	22
100	Prevention of glucocorticoid morbidity in giant cell arteritis. Rheumatology, 2018, 57, ii11-ii21.	1.9	34
101	Hospitalization Increases the Risk of Acute Arthritic Flares in Gout: A Population-based Study over 2 Decades. Journal of Rheumatology, 2018, 45, 1188-1191.	2.0	19
102	Nurses' roles in the management of chronic inflammatory arthritis: a systematic review. Rheumatology International, 2018, 38, 2027-2036.	3.0	6
103	Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis. Annals of the Rheumatic Diseases, 2018, 77, 1311-1317.	0.9	85
104	A Multidisciplinary Delphi Consensus-Based Checklist to Define Clinical Documentation Tools for Both Routine and Research Purposes. Health Services Research and Managerial Epidemiology, 2018, 5, 233339281775416.	0.9	4
105	Outcome of pulmonary sarcoidosis: a population-based study 1976-2013. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 123-128.	0.2	4
106	Risk of gastrointestinal events among patients with sarcoidosis: a population-based study 1976-2013. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2018, 35, 239-244.	0.2	1
107	The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology, 2017, 56, kew273.	1.9	138
108	Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976–2013. European Respiratory Journal, 2017, 49, 1601290.	6.7	58

#	Article	IF	CITATIONS
109	Introduction to the Symposium on Precision Medicine. Mayo Clinic Proceedings, 2017, 92, 4-6.	3.0	4
110	A Randomized, Doubleâ€Blind Trial of Abatacept (CTLAâ€4lg) for the Treatment of Giant Cell Arteritis. Arthritis and Rheumatology, 2017, 69, 837-845.	5.6	271
111	Five-year changes in cardiac structure and function in patients with rheumatoid arthritis compared with the general population. International Journal of Cardiology, 2017, 240, 379-385.	1.7	37
112	Hospitalization Among Patients with Sarcoidosis: A Population-Based Cohort Study 1987–2015. Lung, 2017, 195, 411-418.	3.3	14
113	Antiphospholipid Syndrome. Journal of the American College of Cardiology, 2017, 69, 2317-2330.	2.8	109
114	Polymyalgia Rheumatica. Annals of Internal Medicine, 2017, 166, ITC65.	3.9	49
115	Incidence and Mortality of Physician-Diagnosed Primary Sjögren Syndrome. Mayo Clinic Proceedings, 2017, 92, 734-743.	3.0	42
116	Response. Chest, 2017, 151, 1399.	0.8	0
117	Post-9/11 sarcoidosis in WTC-exposed firefighters and emergency medical service workers. Respiratory Medicine, 2017, 132, 232-237.	2.9	38
118	Malignancy Incidence, Management, and Prevention in Patients with Rheumatoid Arthritis. Rheumatology and Therapy, 2017, 4, 333-347.	2.3	58
119	Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?. Journal of Rheumatology, 2017, 44, 732-739.	2.0	67
120	Contemporary prevalence estimates for giant cell arteritis and polymyalgia rheumatica, 2015. Seminars in Arthritis and Rheumatism, 2017, 47, 253-256.	3.4	61
121	Prevalence of Primary Sjögren's Syndrome in a US Populationâ€Based Cohort. Arthritis Care and Research, 2017, 69, 1612-1616.	3.4	102
122	"Official View―on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements. Arthritis Care and Research, 2017, 69, 1134-1141.	3.4	39
123	Cardiovascular risk assessment in patients with rheumatoid arthritis: a correlative study of noninvasive arterial health testing. Clinical Rheumatology, 2017, 36, 763-771.	2.2	8
124	Uric Acid Is Associated With Inflammation, Coronary Microvascular Dysfunction, and Adverse Outcomes in Postmenopausal Women. Hypertension, 2017, 69, 236-242.	2.7	76
125	Accuracy of Diagnostic Coding for Sarcoidosis in Electronic Databases: A Population-Based Study. Lung, 2017, 195, 713-715.	3.3	10
126	Neurosarcoidosis. Rheumatic Disease Clinics of North America, 2017, 43, 593-606.	1.9	64

#	Article	IF	Citations
127	The Epidemiology of Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis in Olmsted County, Minnesota. Arthritis and Rheumatology, 2017, 69, 2338-2350.	5.6	126
128	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nature Reviews Rheumatology, 2017, 13, 578-592.	8.0	161
129	Clinical Characteristics and Outcome of Hepatic Sarcoidosis: A Population-Based Study 1976–2013. American Journal of Gastroenterology, 2017, 112, 1556-1563.	0.4	52
130	Metabolic control of the scaffold protein TKS5 in tissue-invasive, proinflammatory T cells. Nature Immunology, 2017, 18, 1025-1034.	14.5	103
131	Comment on: Patterns of interstitial lung disease and mortality in rheumatoid arthritis: reply. Rheumatology, 2017, 56, 1825-1825.	1.9	8
132	Polymyalgia rheumatica. Lancet, The, 2017, 390, 1700-1712.	13.7	196
133	Assessment of the frequency of cardiovascular risk factors in patients with Takayasu's arteritis. Rheumatology, 2017, 56, 1939-1944.	1.9	32
134	Increased Risk of Multimorbidity in Patients With Sarcoidosis: A Population-Based Cohort Study 1976 to 2013. Mayo Clinic Proceedings, 2017, 92, 1791-1799.	3.0	15
135	Reliability of Cardiovascular Risk Calculators to Estimate Accurately the Risk of Cardiovascular Disease in Patients With Sarcoidosis. American Journal of Cardiology, 2017, 120, 868-873.	1.6	11
136	Progressive Decline of Lung Function in Rheumatoid Arthritis–Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2017, 69, 542-549.	5.6	139
137	Epidemiology of Polymyalgia Rheumatica 2000–2014 and Examination of Incidence and Survival Trends Over 45 Years: A Populationâ€Based Study. Arthritis Care and Research, 2017, 69, 1282-1285.	3.4	54
138	Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies. Rheumatology International, 2017, 37, 143-149.	3.0	12
139	Association of Sarcoidosis With Increased Risk of VTE. Chest, 2017, 151, 425-430.	0.8	56
140	Influence of Gender on Epidemiology and Clinical Manifestations of Sarcoidosis: A Population-Based Retrospective Cohort Study 1976–2013. Lung, 2017, 195, 87-91.	3.3	46
141	Population-based study of outcomes of patients with juvenile idiopathic arthritis (JIA) compared to non-JIA subjects. Seminars in Arthritis and Rheumatism, 2017, 46, 439-443.	3.4	14
142	Explanatory Style in Patients with Rheumatoid Arthritis: An Unrecognized Predictor of Mortality. Journal of Rheumatology, 2017, 44, 170-173.	2.0	3
143	Decline of rheumatologic care of nursing home residents with rheumatoid arthritis. Rheumatology International, 2017, 37, 1947-1948.	3.0	2
144	FRIO338â€Therapeutic conformity to guidelines and drug-approval in adamantiades-behcet's disease: a retrospective analysis of a middle-european cohort. , 2017, , .		0

#	Article	IF	Citations
145	Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation. Arthritis Research and Therapy, 2017, 19, 212.	3.5	35
146	Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study. Journal of Rheumatology, 2017, 44, 1044-1050.	2.0	11
147	Proposal for an Urgency Score as General Referral Strategy to Second- Care Rheumatology. Annals of Musculoskeletal Medicine, 2017, 1, 001-007.	0.6	1
148	Opioid use in patients with polymyalgia rheumatica. Clinical and Experimental Rheumatology, 2017, 35, 1014-1017.	0.8	2
149	Risk of Malignant Neoplasm in Patients with Incident Rheumatoid Arthritis 1980–2007 in relation to a Comparator Cohort: A Population-Based Study. International Journal of Rheumatology, 2016, 2016, 1-6.	1.6	14
150	Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study. PLoS ONE, 2016, 11, e0149579.	2.5	18
151	Seasonal variation in incidence of sarcoidosis: a population-based study, 1976–2013. Thorax, 2016, 71, 1164-1166.	5.6	23
152	Booster vaccination against tetanus and diphtheria: insufficient protection against diphtheria in young and elderly adults. Immunity and Ageing, 2016, 13, 26.	4.2	29
153	Opioid use in patients with rheumatoid arthritis 2005–2014: a population-based comparative study. Clinical Rheumatology, 2016, 35, 1137-1144.	2.2	56
154	An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome Medicine, 2016, 8, 43.	8.2	596
155	Cancer risk in cutaneous lupus erythematosus: a population-based cohort study. Rheumatology, 2016, 55, 2009-2013.	1.9	25
156	Smoking, obesity and risk of sarcoidosis: A population-based nested case-control study. Respiratory Medicine, 2016, 120, 87-90.	2.9	66
157	Methods for Developing the American College of Rheumatology's Electronic Clinical Quality Measures. Arthritis Care and Research, 2016, 68, 1402-1409.	3.4	13
158	Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis. Science Translational Medicine, 2016, 8, 331ra38.	12.4	201
159	Assessment of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Journal of Rheumatology, 2016, 43, 1947-1949.	2.0	4
160	The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis. BMC Musculoskeletal Disorders, 2016, 17, 363.	1.9	37
161	Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. RMD Open, 2016, 2, e000311.	3.8	31
162	Rheumatology Workforce Planning in Western Countries: A Systematic Literature Review. Arthritis Care and Research, 2016, 68, 1874-1882.	3.4	27

#	Article	IF	Citations
163	Clinical Characteristics of Parotid Gland Sarcoidosis. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 503.	2.2	25
164	Evaluating the Incidence of Arteritic Ischemic Optic Neuropathy and Other Causes of Vision Loss from Giant Cell Arteritis. Ophthalmology, 2016, 123, 1999-2003.	5.2	97
165	Polymyalgia Rheumatica and Giant Cell Arteritis. JAMA - Journal of the American Medical Association, 2016, 315, 2442.	7.4	346
166	Drug prescribing trends in adults with rheumatoid arthritis: a population-based comparative study from 2005 to 2014. Clinical Rheumatology, 2016, 35, 2427-2436.	2.2	7
167	The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Annals of the Rheumatic Diseases, 2016, 75, 560-565.	0.9	148
168	Subgrouping fibromyalgia patients according to response to therapeutic interventions: a new concept for a disease with low treatment-response rates. Rheumatology International, 2016, 36, 447-448.	3.0	2
169	Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. Rheumatic Disease Clinics of North America, 2016, 42, 75-90.	1.9	38
170	Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke. Stroke, 2016, 47, 356-364.	2.0	32
171	Post–September 11, 2001, Incidence of Systemic Autoimmune Diseases in World Trade Center–Exposed Firefighters and Emergency Medical Service Workers. Mayo Clinic Proceedings, 2016, 91, 23-32.	3.0	33
172	Juvenile Idiopathic Arthritis in Olmsted County, Minnesota, 1960–2013. Arthritis and Rheumatology, 2016, 68, 247-254.	5.6	25
173	Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort. Clinical Rheumatology, 2016, 35, 1493-1499.	2.2	5
174	Diagnostic Utility of Angiotensin-Converting Enzyme in Sarcoidosis: A Population-Based Study. Lung, 2016, 194, 91-95.	3.3	145
175	Retrospective Comparison of Open versus Endovascular Procedures for Takayasu Arteritis. Journal of Rheumatology, 2016, 43, 427-432.	2.0	48
176	Whole-body MRI undresses polymyalgia rheumatica. Nature Reviews Rheumatology, 2016, 12, 140-141.	8.0	1
177	Epidemiology of Sarcoidosis 1946-2013. Mayo Clinic Proceedings, 2016, 91, 183-188.	3.0	198
178	Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology, 2016, 55, 347-356.	1.9	131
179	Premature senescence of T-cell subsets in axial spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 748-754.	0.9	39
180	Max Hirsch (1875–1941): His forgotten fate and his contributions to the founding of modern rheumatology. European Journal of Rheumatology, 2016, 3, 101-115.	0.6	1

#	Article	IF	CITATIONS
181	Determinants of Disability in Rheumatoid Arthritis: A Community-Based Cohort Study. Open Rheumatology Journal, 2015, 9, 88-93.	0.2	11
182	The Story of CD4 $<$ sup $>+sup>CD28<sup>â^{^{\prime}}sup>T Cells Revisited: Solved or Still Ongoing?. Journal of Immunology Research, 2015, 2015, 1-11.$	2.2	60
183	Polymyalgia Rheumatica and its Association with Cancer. Rheumatology (Sunnyvale, Calif), 2015, s6, .	0.3	16
184	Increased Incidence of Atrial Fibrillation in Patients with Rheumatoid Arthritis. BioMed Research International, 2015, 2015, 1-5.	1.9	31
185	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Arthritis and Rheumatology, 2015, 67, 2569-2580.	5.6	146
186	Do solar cycles influence giant cell arteritis and rheumatoid arthritis incidence?. BMJ Open, 2015, 5, e006636-e006636.	1.9	21
187	Hospitalization Rates and Utilization Among Patients With Rheumatoid Arthritis. Mayo Clinic Proceedings, 2015, 90, 176-183.	3.0	25
188	Elevation of Serum Immunoglobulin Free Light Chains During the Preclinical Period of Rheumatoid Arthritis. Journal of Rheumatology, 2015, 42, 181-187.	2.0	20
189	Time Trends in Incidence, Clinical Features, and Cardiovascular Disease in Ankylosing Spondylitis Over Three Decades: A Populationâ€Based Study. Arthritis Care and Research, 2015, 67, 836-841.	3.4	39
190	T-cell metabolism in autoimmune disease. Arthritis Research and Therapy, 2015, 17, 29.	3.5	118
191	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group. Journal of Rheumatology, 2015, 42, 2168-2171.	2.0	142
192	Polymyalgia rheumatica: strategies for efficient practice and quality assurance. Rheumatology International, 2015, 35, 1781-1789.	3.0	6
193	Hospitalization rates and utilization among patients with giant cell arteritis: A population-based study from 1987 to 2012. Seminars in Arthritis and Rheumatism, 2015, 45, 70-74.	3.4	11
194	Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor $\hat{l}\pm$ inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Research and Therapy, 2015, 17, 14.	3.5	49
195	Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. European Journal of Internal Medicine, 2015, 26, 285-291.	2.2	224
196	Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Annals of the Rheumatic Diseases, 2015, 74, 1072-1077.	0.9	216
197	Effectiveness and Safety of Anakinra for Management ofÂRefractory Pericarditis. American Journal of Cardiology, 2015, 116, 1277-1279.	1.6	55
198	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2015, 74, 1799-1807.	0.9	220

#	Article	IF	Citations
199	Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2015, 74, 1808-1817.	0.9	74
200	The Detection of Rheumatic Disease through Hospital Diagnoses with Examples of Rheumatoid Arthritis and Giant Cell Arteritis: What Are We Missing?. Journal of Rheumatology, 2015, 42, 2071-2074.	2.0	6
201	Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nature Reviews Cardiology, 2015, 12, 168-176.	13.7	158
202	Visual Manifestations in Giant Cell Arteritis: Trend over 5 Decades in a Population-based Cohort. Journal of Rheumatology, 2015, 42, 309-315.	2.0	103
203	Epidemiology of Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus in a Predominantly White Population in the United States. Arthritis Care and Research, 2015, 67, 817-828.	3.4	113
204	Body mass index and the risk of giant cell arteritis-results from a prospective study. Rheumatology, 2015, 54, 433-440.	1.9	33
205	Large-vessel giant cell arteritis: a cohort study. Rheumatology, 2015, 54, 463-470.	1.9	245
206	Population-based study of QT interval prolongation in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2015, 33, 84-9.	0.8	30
207	The Influence of Early Menopause on Cardiovascular Risk in Women with Rheumatoid Arthritis. Journal of Rheumatology, 2014, 41, 1270-1275.	2.0	12
208	Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study. Annals of the Rheumatic Diseases, 2014, 73, 1811-1818.	0.9	29
209	Hospitalized Infections in Giant Cell Arteritis â€" A Population-based Retrospective Cohort Study. Journal of Rheumatology, 2014, 41, 2447-2451.	2.0	10
210	Longterm Blood Pressure Variability in Patients with Rheumatoid Arthritis and Its Effect on Cardiovascular Events and All-cause Mortality in RA: A Population-based Comparative Cohort Study. Journal of Rheumatology, 2014, 41, 1638-1644.	2.0	10
211	5. Biomarkers in PMR, GCA and other large vessel arteritides. Rheumatology, 2014, 53, i3-i4.	1.9	O
212	Hyperuricemia and Incident Cardiovascular Disease and Noncardiac Vascular Events in Patients with Rheumatoid Arthritis. International Journal of Rheumatology, 2014, 2014, 1-7.	1.6	22
213	The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 338-347.	2.4	977
214	The safety of biologic therapies in RA-associated interstitial lung disease. Nature Reviews Rheumatology, 2014, 10, 284-294.	8.0	74
215	Clinical implementation of musculoskeletal ultrasound in rheumatology in Austria. Rheumatology International, 2014, 34, 1111-1115.	3.0	9
216	Cardiovascular disease assessment in rheumatoid arthritis: a guide to translating knowledge of cardiovascular risk into clinical practice. Annals of the Rheumatic Diseases, 2014, 73, 1284-1288.	0.9	49

#	Article	IF	CITATIONS
217	Development of Reduced Kidney Function in Rheumatoid Arthritis. American Journal of Kidney Diseases, 2014, 63, 206-213.	1.9	76
218	A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest, 2014, 145, 454-463.	0.8	67
219	Antiphospholipid Antibodies Predict Progression of Abdominal Aortic Aneurysms. PLoS ONE, 2014, 9, e99302.	2.5	17
220	Perioperative management of the patient with rheumatoid arthritis. World Journal of Orthopedics, 2014, 5, 283.	1.8	53
221	Elderly―versus younger―nset rheumatoid arthritis: Higher levels of ultrasoundâ€detected inflammation despite comparable clinical disease activity. Arthritis Care and Research, 2013, 65, 304-308.	3.4	16
222	L15. EULAR/ACR 2012 classification criteria for polymyalgia rheumatica. Presse Medicale, 2013, 42, 543-546.	1.9	1
223	Occurrence of gout in rheumatoid arthritis: it does happen! A population-based study. International Journal of Clinical Rheumatology, 2013, 8, 433-437.	0.3	14
224	NKG ₂ D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Annals of the Rheumatic Diseases, 2013, 72, 1852-1859.	0.9	44
225	THU0214â€Treatment of refractory giant cell arteritis with cyclophosphamide. A retrospective analysis of 35 patients from three tertiary care centers. Annals of the Rheumatic Diseases, 2013, 71, 227.3-228.	0.9	3
226	Recall Responses to Tetanus and Diphtheria Vaccination Are Frequently Insufficient in Elderly Persons. PLoS ONE, 2013, 8, e82967.	2.5	51
227	FRIO211â€The role of NKG2D, CX3CR1 and TLR4 in the pathogenesis of giant cell arteritis. Annals of the Rheumatic Diseases, 2013, 71, 385.2-385.	0.9	0
228	Challenges in the diagnosis of chronic immune-mediated rheumatic diseases. Discovery Medicine, 2013, 15, 160-5.	0.5	4
229	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Annals of the Rheumatic Diseases, 2012, 71, 484-492.	0.9	451
230	Abdominal Aortic Aneurysms. Journal of Primary Care and Community Health, 2012, 3, 142-147.	2.1	0
231	Diagnosis and assessment of polymyalgia rheumatica: a step forward. Aging Health, 2012, 8, 395-397.	0.3	2
232	Patient-reported Outcomes in Polymyalgia Rheumatica. Journal of Rheumatology, 2012, 39, 795-803.	2.0	64
233	Anti-synthetase syndrome presenting as cryptogenic organizing pneumonia. Respiratory Medicine Case Reports, 2012, 6, 13-15.	0.4	4
234	Magnetic Resonance Elastography for Liver Fibrosis in Methotrexate Treatment. Open Journal of Rheumatology and Autoimmune Diseases, 2012, 02, 6-13.	0.2	9

#	Article	IF	Citations
235	Ultrasound-Defined Remission and Active Disease in Rheumatoid Arthritis: Association with Clinical and Serologic Parameters. Seminars in Arthritis and Rheumatism, 2012, 41, 761-767.	3.4	36
236	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis and Rheumatism, 2012, 64, 943-954.	6.7	273
237	Apoptotic Effects of Antilymphocyte Globulins on Human Pro-inflammatory CD4+CD28â^' T-cells. PLoS ONE, 2012, 7, e33939.	2.5	17
238	History of vasculitis: The life and work of Adolf Kussmaul. Cleveland Clinic Journal of Medicine, 2012, 79, S54-S56.	1.3	4
239	Advances in the evaluation and classification of chronic inflammatory rheumatic diseases. Discovery Medicine, 2012, 13, 299-304.	0.5	4
240	Treatment of refractory giant cell arteritis with cyclophosphamide:a retrospective analysis of 35 patients from three centres. Clinical and Experimental Rheumatology, 2012, 30, S70-6.	0.8	30
241	Similar performance of DAS-28, CDAI, and SDAI in rheumatoid arthritis patients with and without sonographic signs of active inflammation in routine clinical practice. Scandinavian Journal of Rheumatology, 2011, 40, 234-236.	1.1	7
242	Ultrasonography in inflammatory rheumatic disease: an overview. Nature Reviews Rheumatology, 2011, 7, 479-488.	8.0	38
243	Post-thymic regulation of CD5 levels in human memory T cells is inversely associated with the strength of responsiveness to interleukin-15. Human Immunology, 2011, 72, 627-631.	2.4	22
244	Investigation of bacterial and viral agents and immune status in Behcet's disease patients from Iran. International Journal of Rheumatic Diseases, 2011, 14, 298-310.	1.9	9
245	Polymyalgia rheumatica and giant cell arteritis: management of two diseases of the elderly. Aging Health, 2011, 7, 633-645.	0.3	19
246	Major vessel involvement in Behçet's disease: an update. Current Opinion in Rheumatology, 2011, 23, 24-31.	4.3	170
247	Editorial [Hot Topic: Aging and Immune-Mediated Diseases (Guest Editors: Christian Dejaco, Christina) Tj ETQq1 1	0.784314 1.2	l 4 rgBT /Over
248	Early Aged T-Cells in Immune-Mediated Diseases. Current Immunology Reviews, 2011, 7, 124-132.	1.2	1
249	Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. Annals of the Rheumatic Diseases, 2011, 70, 447-453.	0.9	81
250	The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis and Rheumatism, 2011, 63, 633-639.	6.7	425
251	Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica. Rheumatology International, 2010, 30, 297-303.	3.0	46
252	Third generation anti-cyclic citrullinated peptide antibodies do not predict anti-TNF-α treatment response in rheumatoid arthritis. Rheumatology International, 2010, 30, 451-454.	3.0	10

#	Article	IF	Citations
253	The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project. Clinical Rheumatology, 2010, 29, 167-174.	2.2	6
254	Increase in age at onset of giant cell arteritis: a population-based study. Annals of the Rheumatic Diseases, 2010, 69, 780-781.	0.9	82
255	Unraveling the tautology of polymyalgia rheumatica. Nature Reviews Rheumatology, 2010, 6, 249-250.	8.0	9
256	Fusion of Real-time US with CT Images to Guide Sacroiliac Joint Injection in Vitro and in Vivo. Radiology, 2010, 256, 547-553.	7.3	62
257	Neopterin: Marker of coronary artery disease activity, severity and/or extent in patients with clinically stable angina?. International Journal of Cardiology, 2010, 144, 75-76.	1.7	1
258	Detection of vascularity in wrist tenosynovitis: power Doppler ultrasound compared to contrast-enhanced grey-scale ultrasound. Arthritis Research and Therapy, 2010, 12, R209.	3.5	28
259	Rheumatologie. , 2010, , 723-756.		0
260	Which Measure of Inflammation to Use? A Comparison of Erythrocyte Sedimentation Rate and C-Reactive Protein Measurements from Randomized Clinical Trials of Golimumab in Rheumatoid Arthritis. Journal of Rheumatology, 2009, 36, 1606-1610.	2.0	81
261	Reliability Exercise for the Polymyalgia Rheumatica Classification Criteria Study: The Oranjewoud Ultrasound Substudy. International Journal of Rheumatology, 2009, 2009, 1-5.	1.6	23
262	Antibodies against mutated citrullinated vimentin fail to predict anti‶NFα treatment response in rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2009, 38, 66-67.	1.1	7
263	13th International Conference on Behçet's Disease, May 24–27, 2008, Pörtschach am Wörthersee, Austria. Journal of Rheumatology, 2009, 36, 1312-1317.	2.0	4
264	An outbreak of norovirus gastroenteritis in an Austrian hospital, winter 2006–2007. Wiener Klinische Wochenschrift, 2009, 121, 137-143.	1.9	27
265	Neopterin, CD4+CD28â^ lymphocytes and the extent and severity of coronary artery disease. International Journal of Cardiology, 2009, 135, 27-35.	1.7	42
266	Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic. Rheumatology International, 2008, 29, 69-73.	3.0	2
267	4Âyears after withdrawal of rofecoxib: where do we stand today?. Rheumatology International, 2008, 28, 1187-1195.	3.0	21
268	Remitting seronegative syndrome with pitting edema as the presenting symptom in a young, male patient with sarcoidosis: A case report. Arthritis and Rheumatism, 2008, 59, 148-152.	6.7	4
269	Feasibility of ultrasoundâ€guided sacroiliac joint injection considering sonoanatomic landmarks at two different levels in cadavers and patients. Arthritis and Rheumatism, 2008, 59, 1618-1624.	6.7	101
270	Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. Journal of Rheumatology, 2008, 35, 270-7.	2.0	61

#	Article	IF	Citations
271	Anti-TNF therapy in the management of Behcet's disease–review and basis for recommendations. Rheumatology, 2007, 46, 736-741.	1.9	292
272	Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Annals of the Rheumatic Diseases, 2007, 67, 1292-1298.	0.9	51
273	Tumor necrosis factor antagonists and cancer in patients with rheumatoid arthritis. Nature Clinical Practice Rheumatology, 2007, 3, 14-15.	3.2	4
274	Value of contrast-enhanced ultrasound in rheumatoid arthritis. European Journal of Radiology, 2007, 64, 222-230.	2.6	61
275	CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis. Arthritis and Rheumatism, 2007, 56, 43-57.	6.7	70
276	Lack of influence of body mass index on efficacy and tolerance of acemetacin in short-term treatment of musculoskeletal diseases. Rheumatology International, 2007, 27, 351-355.	3.0	2
277	Use of the European preliminary criteria, the Breiman-classification tree and the American–European criteria for diagnosis of primary Sjögren's Syndrome in daily practice: a retrospective analysis. Rheumatology International, 2007, 27, 699-702.	3.0	20
278	Lack of microbial DNA in tissue specimens of patients with abdominal aortic aneurysms and positive Chlamydiales serology. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 141-145.	2.9	11
279	Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Research and Therapy, 2006, 8, R119.	3.5	115
280	Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease—A randomized, placebo-controlled study. American Heart Journal, 2006, 151, 139.e1-139.e7.	2.7	33
281	Abdominal aortic aneurysms: an underestimated type of immune-mediated large vessel arteritis?. Current Opinion in Rheumatology, 2006, 18, 48-53.	4.3	13
282	Imbalance of regulatory T cells in human autoimmune diseases. Immunology, 2006, 117, 289-300.	4.4	324
283	Increasing Evidence for Immune-Mediated Processes and New Therapeutic Approaches in Abdominal Aortic Aneurysms–A Review. Annals of the New York Academy of Sciences, 2006, 1085, 331-338.	3.8	9
284	Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clinical Rheumatology, 2006, 25, 334-337.	2.2	101
285	Are regulatory T-cells linked with aging?. Experimental Gerontology, 2006, 41, 339-345.	2.8	115
286	Polymyalgia rheumatica: The mess we are now in and what we need to do about it. Arthritis and Rheumatism, 2006, 55, 518-520.	6.7	37
287	Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis and Rheumatism, 2006, 54, 3310-3318.	6.7	303
288	To the editor - Eur. J. Immunol. 1/2006. European Journal of Immunology, 2006, 36, 245-246.	2.9	14

#	Article	IF	Citations
289	High positive predictive value of specific antibodies cross-reacting with a 28-kDa Drosophila antigen for diagnosis of ankylosing spondylitis. Rheumatology, 2006, 45, 38-42.	1.9	13
290	Positive and negative predictive values from published studies can be misleading for decision-making in clinical practice: reply. Rheumatology, 2006, 45, 780-781.	1.9	2
291	18F-Flourodeoxyglucose positron emission tomography in polymyalgia rheumatica: novel insight into complex pathogenesis but questionable use in predicting relapses. Rheumatology, 2006, 46, 559-560.	1.9	6
292	Preferential type 1 chemokine receptors and cytokine production of CD28- T cells in ankylosing spondylitis. Annals of the Rheumatic Diseases, 2006, 65, 647-653.	0.9	26
293	CD8 + T-Cell Subpopulations in Human Abdominal Aortic Aneurysm Lesion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, e19; author reply e19-20.	2.4	3
294	Induction of Tolerance in Autoimmune Diseases Rather Than Cure of Cancer by Interleukin-2 Therapy. Journal of Clinical Oncology, 2006, 24, e34-e34.	1.6	4
295	Major vessel involvement in Beh??et disease. Current Opinion in Rheumatology, 2005, 17, 1-8.	4.3	130
296	Contrast enhanced gray-scale sonography in assessment of joint vascularity in rheumatoid arthritis: results from the IACUS study group. European Radiology, 2005, 15, 2404-2410.	4.5	126
297	Remitting seronegative symmetrical synovitis with pitting edema of the hands: Ultrasound, color doppler ultrasound, and magnetic resonance imaging findings. Arthritis and Rheumatism, 2005, 53, 226-233.	6.7	36
298	Inflammatory low back pain: High negative predictive value of contrast-enhanced color Doppler ultrasound in the detection of inflamed sacroiliac joints. Arthritis and Rheumatism, 2005, 53, 440-444.	6.7	105
299	Etanercept therapy for immune-mediated cochleovestibular disorders: A multi-center, open-label, pilot study. Arthritis and Rheumatism, 2005, 53, 337-342.	6.7	82
300	Modulation of CD28 expression with anti–tumor necrosis factor α therapy in rheumatoid arthritis. Arthritis and Rheumatism, 2005, 52, 2996-3003.	6.7	126
301	Reduced aortic elastic properties in a child with Takayasu arteritis: case report and literature review. European Journal of Pediatrics, 2005, 164, 685-690.	2.7	10
302	High Prevalence of Circulating CD4 ⁺ CD28 ^{â^'} T-Cells in Patients With Small Abdominal Aortic Aneurysms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1347-1352.	2.4	78
303	PP21. ANOMALOUS EXPRESSION OF TOLL-LIKE RECEPTORS ON CD4+CD28NULL T-CELLS PROMOTES INTERFERON-Î ³ PRODUCTION IN GIANT CELL ARTERITIS/POLYMYALGIA RHEUMATICA. Rheumatology, 2005, 44, iii21-iii21.	1.9	0
304	Between adaptive and innate immunity: TLR4-mediated perforin production by CD28null T-helper cells in ankylosing spondylitis. Arthritis Research and Therapy, 2005, 7, R1412.	3.5	44
305	Contrast-Enhanced Ultrasound in Rheumatic Joint Diseases. , 2005, , 365-379.		6
306	Value of Transducer Positions in the Measurement of Finger Flexor Tendon Thickness by Sonography. Journal of Ultrasound in Medicine, 2004, 23, 331-337.	1.7	26

#	Article	IF	CITATIONS
307	Therapeutic effects of gemcitabine on cutaneous manifestations in an Adamantiades-Behcet's disease-like mouse model. Experimental Dermatology, 2004, 13, 630-634.	2.9	9
308	Letter to the Editor. European Radiology, 2004, 14, 545-546.	4.5	15
309	Prognostic markers of radiographic progression in early rheumatoid arthritis. Arthritis and Rheumatism, 2004, 50, 43-54.	6.7	160
310	Quantitative assessment of periarticular osteopenia in patients with early rheumatoid arthritis: a preliminary report. Scandinavian Journal of Rheumatology, 2004, 33, 307-311.	1.1	13
311	Venous thromboembolism in long-distance air travellers. Lancet, The, 2004, 363, 896.	13.7	2
312	Workshop report: clinical diagnosis and imaging of sacroilitis, Innsbruck, Austria, October 9, 2003. Journal of Rheumatology, 2004, 31, 2041-7.	2.0	10
313	18F-Fluorodeoxyglucose-positron emission tomography: A new explorative perspective. Experimental Gerontology, 2003, 38, 463-470.	2.8	27
314	Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or) Tj ETQq0 0 0 rgE Arthritis and Rheumatism, 2003, 48, 3522-3531.	3T /Overlo 6.7	ck 10 Tf 50 4 479
315	Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery) Tj ETQq1 1 0.78431 Rheumatism, 2003, 48, 3532-3537.	4 rgBT /O 6.7	verlock 10 T 176
316	Fibromyalgia may mask onset of autoimmune diseases. European Journal of Pain, 2003, 7, 295-296.	2.8	3
317	Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis. Arthritis Research, 2003, 5, R292.	2.0	83
318	Splinting vs Surgery for Carpal Tunnel SyndromeSplinting vs Surgery for Carpal Tunnel Syndrome. JAMA - Journal of the American Medical Association, 2003, 289, 420.	7.4	4
319	Generalized Large Vessel Arteritis Visualized by 18 Fluorodeoxyglucose-Positron Emission Tomography. Circulation, 2003, 107, 923-923.	1.6	15
320	Think clearly, be sincere, act calmly: Adolf Kussmaul (February 22, 1822–May 28, 1902) and his relevance to medicine in the 21st century. Current Opinion in Rheumatology, 2003, 15, 29-34.	4.3	15
321	Valvular Disease and Myocardial Infarctions in a Patient With Behçet Disease. Journal of Clinical Rheumatology, 2003, 9, 316-320.	0.9	11
322	Splinting vs Surgery for Carpal Tunnel Syndrome. JAMA - Journal of the American Medical Association, 2003, 289, 421.	7.4	0
323	New Perspectives of Imaging Techniques for Diagnosis of Organ Manifestations in Behçet's Disease. , 2003, 528, 445-448.		O
324	18-F-FDG-Positron Emission Tomography for Diagnosis of Large Vessel Arteritis in Behçet's Disease. , 2003, 528, 435-436.		13

#	Article	IF	CITATIONS
325	Splinting vs Surgery for Carpal Tunnel Syndrome. JAMA - Journal of the American Medical Association, 2003, 289, 421-a-421.	7.4	0
326	Circulating cytotoxic CD8(+) CD28(-) T cells in ankylosing spondylitis. Arthritis Research, 2002, 4, 71.	2.0	97
327	Vascular Endothelial Growth Factor (VEGF) in Ankylosing Spondylitis - a Pilot Study. Wiener Medizinische Wochenschrift, 2002, 152, 223-225.	1.1	17
328	The value of contrast-enhanced color doppler ultrasound in the detection of vascularization of finger joints in patients with rheumatoid arthritis. Arthritis and Rheumatism, 2002, 46, 647-653.	6.7	190
329	Historical perspective of vasculitis: Polyarteritis nodosa and microscopic polyangiitis. Current Rheumatology Reports, 2002, 4, 67-74.	4.7	11
330	Randomized double blind trial of an extract from the pentacyclic alkaloid-chemotype of uncaria tomentosa for the treatment of rheumatoid arthritis. Journal of Rheumatology, 2002, 29, 678-81.	2.0	56
331	A patient remembers the miracle drug cortisone 50 years later. Minnesota Medicine, 2002, 85, 12-5.	0.1	0
332	Open trial of methotrexate as treatment for autoimmune hearing loss. Arthritis and Rheumatism, 2001, 45, 146-150.	6.7	50
333	Historical perspective on the classification of vasculitis. Arthritis and Rheumatism, 2000, 13, 122-127.	6.7	10
334	Notes on the history of eponymic idiopathic vasculitis: The diseases of Henoch and Sch�nlein, Wegener, Churg and Strauss, Horton, Takayasu, Beh�et, and Kawasaki. Arthritis and Rheumatism, 2000, 13, 237-245.	6.7	40
335	Clonality and Longevity of CD4+CD28null T Cells Are Associated with Defects in Apoptotic Pathways. Journal of Immunology, 2000, 165, 6301-6307.	0.8	157
336	New Rearrangement Pattern after Treatment of Hairy-Cell Leukemia with 2-Chlorodeoxyadenosine. Acta Haematologica, 2000, 103, 109-111.	1.4	0
337	Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia. Leukemia Research, 1999, 23, 1121-1126.	0.8	9
338	A history of early investigation in polyarteritis nodosa. Arthritis and Rheumatism, 1999, 12, 294-302.	6.7	17
339	GEMCITABINE-A NOVEL IMMUNOSUPPRESSIVE AGENT-PREVENTS REJECTION IN A RAT CARDIAC TRANSPLANTATION MODEL1. Transplantation, 1999, 68, 1051-1053.	1.0	11
340	Severe deep white matter lesions and outcome in major depressive disorder. BMJ: British Medical Journal, 1999, 318, 737-737.	2.3	2
341	Entamoeba hartmanni: a new causative agent in the pathogenesis of reactive arthritis?. Rheumatology International, 1998, 18, 37-38.	3.0	10
342	Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2′,2′-difluorodeoxycytidine on human hepatoma HepG2 cells. Journal of Hepatology, 1998, 28, 504-509.	3.7	31

#	Article	IF	CITATIONS
343	Aging-related Deficiency of CD28 Expression in CD4+ T Cells Is Associated with the Loss of Gene-specific Nuclear Factor Binding Activity. Journal of Biological Chemistry, 1998, 273, 8119-8129.	3.4	169
344	Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28-T cells from rheumatoid arthritis patients. Journal of Immunology, 1998, 161, 1018-25.	0.8	143
345	Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity. Experimental Hematology, 1998, 26, 1223-8.	0.4	35
346	A Comparison of the Antiproliferative Properties of Recombinant Human IFN-α2 and IFN-ω in Human Bone Marrow Culture. Journal of Interferon and Cytokine Research, 1997, 17, 327-329.	1.2	10
347	The Safety Profile of Low-dose Cladribine in Refractory Rheumatoid Arthritis. Scandinavian Journal of Rheumatology, 1997, 26, 376-379.	1.1	33
348	T Cells and Natural Killer Cells after Treatment of Hairy Cell Leukaemia with 2-Chlorodeoxyadenosine. Acta Haematologica, 1997, 97, 180-183.	1.4	14
349	Active compression–decompression cardiopulmonary resuscitation in standing position over the patient: pros and cons of a new method. Resuscitation, 1997, 34, 7-10.	3.0	6
350	Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. , 1996, 28, 172-181.		25
351	Rescuer's work capacity and duration of cardiopulmonary resuscitation. Resuscitation, 1996, 33, 135-139.	3.0	36
352	Local application of antimycotics in mucormycosis cerebri: a case report Journal of Neurology, Neurosurgery and Psychiatry, 1996, 61, 521-522.	1.9	6
353	2-Chlorodeoxyadenosine (2-CdA) in chronic lymphocytic leukemia refractory to fludarabine?. Leukemia, 1996, 10, 1253-4.	7.2	0
354	Critical aspects of active compression-decompression CPR. Acta Anaesthesiologica Scandinavica, Supplement, 1996, 109, 109-11.	0.0	0
355	Minimal Residual Disease in Hairy-cell Leukemia after Treatment with 2-chlorodeoxyadenosine. Blood Cells, Molecules, and Diseases, 1995, 21, 142-151.	1.4	17
356	Economic and Quality-of-Life Impact of NSAIDs in Rheumatoid Arthritis. Pharmacoeconomics, 1995, 8, 479-490.	3.3	13
357	Acyclovir in acute oligoarticular herpetic arthritis. Lancet, The, 1995, 346, 712-713.	13.7	2
358	The immunosuppressive substance 2-chloro-2-deoxyadenosine modulates lipoprotein metabolism in a murine macrophage cell line (P388 cells). Lipids, 1994, 29, 627-633.	1.7	4
359	Fulminant hepatitis C virus infection. Lancet, The, 1994, 343, 1433.	13.7	3
360	Idiopathic inflammatory myopathy of the antisynthetase (jo-1) type associated with noncaseating granulomas. Arthritis and Rheumatism, 1993, 36, 1743-1747.	6.7	12

ı	#	Article	IF	CITATIONS
	361	Identification of the benzothiazepine-binding polypeptide of skeletal muscle calcium channels with (+)-cis-azidodiltiazem and anti-ligand antibodies. Journal of Biological Chemistry, 1990, 265, 363-70.	3.4	35
	362	Risk factors for falls and their impact on the severity of fall-related injuries. Healthy Aging Research, 0, , .	0.3	0